Zimmer Biomet Q3 2022 Earnings Report
Key Takeaways
Zimmer Biomet's third quarter net sales were $1.670 billion, a decrease of 0.9% over the prior year, but increased 5.0% on a constant currency basis. Net earnings were $194.0 million, or $333.1 million on an adjusted basis. Diluted earnings per share were $0.92, and adjusted diluted earnings per share were $1.58.
Third quarter net sales from continuing operations of $1.670 billion decreased 0.9% and increased 5.0% on a constant currency basis
Third quarter diluted earnings per share from continuing operations were $0.92; adjusted diluted earnings per share from continuing operations were $1.58
Company updates 2022 financial guidance, raising range for full year outlook
Aligned with the ongoing transformation of Zimmer Biomet's business, key third quarter highlights include announcement of a first-of-its-kind, three-year agreement with Hospital for Special Surgery (HSS) to create the HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI) in Robotic Joint Replacement
Zimmer Biomet
Zimmer Biomet
Zimmer Biomet Revenue by Segment
Forward Guidance
Company updates 2022 financial guidance, raising range for full year outlook
Revenue & Expenses
Visualization of income flow from segment revenue to net income